The trajectory of companies tied to flagship drugs like Viagra presents a complex investment picture. While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the loss of exclusivity in key markets has introduced considerable uncertainty . Investors are now assessing the consequences of gener